Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXON 19 DELETION
(
ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/882
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/133
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Afatinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22452895
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Afatinib | Sensitivity | true |